How to vet a provider
Dozens of companies will sell you a GLP-1 or a peptide online. Some are run by licensed clinicians working with named pharmacies. Others are storefronts. The difference is checkable in about ten minutes, and this page is how.
The five checks
Run all five. A provider that passes four and fails one is still a provider that fails.
| Check | What good looks like | How to verify |
|---|---|---|
| 1. A real clinical evaluation | A licensed clinician reviews your history and can decline to prescribe. You can reach them with a question afterward. | Look for a named clinician and a path to follow-up. A questionnaire where every answer leads to the same prescription is not an evaluation. |
| 2. A named, licensed pharmacy | The provider tells you which 503A or 503B pharmacy makes the medication, by name, before you pay. | Ask directly. Check the pharmacy's license with that state's board of pharmacy. Evasion is the answer. |
| 3. Licensed in your state | The prescribing clinician holds a license where you live. | Your state medical board's license lookup, which is free and public. |
| 4. LegitScript certification | Active certification, verifiable on LegitScript's own site rather than a badge on the seller's page. | Search the provider at legitscript.com. A badge image proves nothing; the entry in their database does. |
| 5. No open FDA warning letter | Nothing outstanding against the company or its compounding pharmacy. | Search the FDA's warning letter database by company name. |
Two more worth doing if the provider dispenses compounded medication: NABP digital pharmacy accreditation, searchable at nabp.pharmacy, and whether the company will send you a certificate of analysis for the batch.
Why the FDA checks matter right now
This is not a hypothetical concern. The agency has run a sustained enforcement campaign against this market:
- More than 100 letters went to telehealth and compounding providers over false or misleading GLP-1 claims during 2025.
- 30 telehealth companies received warning letters on 20 February 2026.
- 25 more followed on 16 June 2026.
The violations named in the June letters are worth knowing, because they describe exactly what to watch for. Companies claimed their compounded products had been FDA-approved or evaluated for safety and effectiveness when they had not. Companies described the pharmacy they source from as "FDA-approved" or "FDA-licensed," which is not something the agency grants to compounders. And in some cases the product label pictured on the site implied the company compounded the drug itself when it did not.
If you see any of those three claims on a provider's website, you have learned something useful about that provider.
Red flags
- "Same as brand name" or "FDA-approved pharmacy." Neither phrase can be true of a compounded product.
- No pharmacy named anywhere on the site.
- No way to speak to a clinician after you have paid.
- A price that only appears after you have completed an intake quiz.
- A large annual prepayment required to get the advertised rate.
- Pressure to increase your dose faster than the approved label's schedule.
- Selling peptides that have no legal route at all. If a site offers BPC-157 injections alongside things with no lawful pathway, its compliance standards are telling you something.
Questions to ask before you pay
- Which pharmacy compounds this, and in what state?
- Is this the base form or a salt form, and which one?
- What will I pay per month at a maintenance dose, six months from now?
- What happens if I have a side effect at 9pm on a Saturday?
- Can I cancel monthly, and what happens to a prepaid balance?
- Will you send me the certificate of analysis for my batch?
On this page and money. Amino Desk has no provider partnerships at this time. If that changes, any page with a paid link will say so at the top, and the checks above will stay exactly as they are written here.
Sources
- McDermott Will & Emery: FDA's June 2026 warning letters and the violations cited
- Bloomberg Law: FDA warns companies over misleading claims, June 2026
- Telehealth.org: the February 2026 letters and the 2025 wave
- Klarity: verification checklist for GLP-1 telehealth
- RAPS: FDA citations of telehealth firms, June 2026